[Experiences and perspectives on adjuvant chemotherapy in osteogenic osteosarcoma].
This article analyses the relevance of the published results of adjuvant chemotherapy in osteogenic osteosarcomas. It discusses the causation and prospects for treatment particularly the details of the chemotherapy, with reference to mono- or poly-chemotherapy, the influence of the dose and of the interval of administration, and also the value of pre- and post-operative chemotherapy. It is apparent that intensive pre-operative chemotherapy limited to 4 weeks is a reasonable mean of distinguishing the good responders. The problem of the choice of therapy for bad responders is also discussed.
Jasmin
C
C
Delépine
G
G
Delépine
N
N
Trifaud
A
A
Mathé
G
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery
Acquis et perspectives de la chimiothérapie adjuvante des ostéosarcomes ostéogéniques.